Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index; 48 of the 102 sources its claims cite were checked for support.

Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review

Open access
Özgen, Heval, Spijkerman, Renske, Noack, Moritz, Holtmann, Martin, Schellekens, Arnt, Dalsgaard, Søren, van den Brink, Wim, Hendriks, Vincent · 2021 · Journal of Clinical Medicine

Abstract

Systematic review of treatment in adolescents with ADHD and SUD, including review of longitudinal medication-SUD links.

Overview

CoChat Summary

TL;DR

This systematic review found that evidence for treating adolescents with concurrent ADHD and substance use disorder (SUD) is very limited, and no pharmacological trial showed a robust between-group effect on either ADHD or SUD. In contrast, ADHD medications showed moderate-to-large benefits for ADHD symptoms in adolescents without SUD, while psychosocial and complementary approaches lacked strong evidence in either group.

Key findings

  • The review included 4 placebo-controlled pharmacological trials in adolescents with concurrent ADHD and SUD (458 enrolled patients) and 12 placebo-controlled pharmacological trials in adolescents with ADHD without SUD (2675 patients).
  • In the comorbid ADHD+SUD trial by Riggs et al. (2011), 303 adolescents received OROS-methylphenidate or placebo plus weekly CBT/MI for SUD; both groups improved on self-reported ADHD symptoms and substance-use days, but no between-group difference was found on the primary outcomes.
  • Across the four pharmacological trials in adolescents with ADHD and SUD, the evidence base was less than 500 patients and none showed a robust treatment effect on ADHD or SUD.
  • In adolescents with ADHD without SUD, the review reports significant ADHD symptom improvements with active medication, with effect sizes in the moderate-to-large range: MPH d = 0.53–1.33, LDX d = 0.80–1.23, MAS-XR d = 0.80, pemoline d = 2.05, atomoxetine d = 0.99, and guanfacine d = 0.52.
  • For childhood ADHD and later SUD, the review reports increased later SUD risk in meta-analyses with mean odds ratios ranging from 1.34 to 3.48, and one prospective study found a hazard ratio of 1.77 versus healthy controls; some longitudinal studies suggested stimulant treatment may be protective, including a 31% lower rate of substance-related events in one registry study and a 14% to 19% reduction in odds of SUD-related emergency visits in another.

Methods

  • Systematic review of studies published 2000 to 11 April 2021, searching Medline, PsycINFO, and the Cochrane Database of Systematic Reviews, plus reference lists.
  • Included original English-language controlled studies and meta-analyses on ADHD treatment in adolescents 12–20 years old, with ADHD diagnosed by DSM-IV/-5 or ICD-10/-11 criteria; studies had to report validated ADHD outcomes and, for comorbid SUD, quantitative substance-use outcomes.
  • Study selection and data extraction were done by review authors on full texts, with risk of bias assessed using Cochrane RoB-2 and evidence quality rated with the SIGN grading system.

Limitations

  • The paper states that the evidence for adolescents with concurrent ADHD and SUD is limited, does not support strong recommendations, and that more research is needed.
  • For psychosocial treatment, the paper says there were no randomized trials or meta-analyses in youth with concurrent ADHD and SUD, and for complementary interventions in that group, research was absent.
  • Evident from the text: many included studies had high risk of bias, short follow-up, substantial between-study heterogeneity, and in some cases small samples or no separate adolescent outcomes; the paper also notes that some conclusions about long-term effects cannot be firm because extension studies were open-label and involved only selected participants.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jcm10173908

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart.
Figure 1 Flowchart.CC BY · PubMed Central

Verification

Claims the paper makes

31 Valid · 4 Not valid · 19 Not checked · 58 Own results and interpretations

48 more claims · 9 with their cited sources checked

Create a free account to see all 112 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 51
  • Probably not a substantial claim. 9
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Cited by

See all 27

Metadata

Authors
Özgen, H., Spijkerman, R., Noack, M., Holtmann, M., Schellekens, A., Dalsgaard, S., van den Brink, W., & Hendriks, V.
Affiliations
  • Parnassia Addiction Research Centre (PARC), Parnassia Psychiatric Institute, 2512 HN The Hague, The Netherlands
  • Parnassia Groep (NL)
  • LWL-Universitätsklinik Hamm (DE)
  • Radboud University Nijmegen (NL)
  • Aarhus University (DK)
  • International Collaboration on ADHD and Substance Abuse (ICASA) Foundation, 6500 HE Nijmegen, The Netherlands
  • Leiden University Medical Center (NL)
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2021-08-30
Volume
10
Issue
17
Pages
3908
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3197422577
Cited by
27
References
90
Citations by year
2026: 7 · 2025: 9 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 1
FWCI
0.49
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
attention deficit hyperactivity disorder, substance use disorders, comorbidities, adolescents, stimulant pharmacotherapy, cognitive behavioral therapy, psychosocial interventions, complementary therapy, childhood ADHD, substance use prevention, treatment effectiveness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. https://app.cochat.ai/papers/10.3390/jcm10173908
The paper
Özgen, H., Spijkerman, R., Noack, M., Holtmann, M., Schellekens, A., Dalsgaard, S., van den Brink, W., & Hendriks, V. (2021). Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10173908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.